Home | Business News | Browse by Publication | P | Pharma Marketletter

Accentia agrees with FDA on Revimmune trial.

Publication: Pharma Marketletter
Publication Date: 15-OCT-07
Format: Online
Delivery: Immediate Online Access
Full Article Title: Accentia agrees with FDA on Revimmune trial.(Brief article)

Article Excerpt
Florida, USA-based Accentia Biopharmaceuticals says that it met with the Food and Drug Administration for a scheduled pre-Investigational New Drug review of Revimmune, an intravenous form of cyclophosamide. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase III randomized controlled, multicenter clinical...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
UCB's Neupro effective for motor impairment in PD.(Brief article), October 15, 2007
Mayo Clinic team uses Ab to trigger remyelination.(Antibodies)(Brief a..., October 15, 2007
New tool for R&D from Symyx Tech.(Symyx Technologies)(research and dev..., October 15, 2007
Mimotopes in deal with BHRI.(Baker Heart Research Institute)(Brief art..., October 15, 2007
Bioenvision and Genzyme file petition on merger.(Brief article), October 15, 2007

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.